Corey N. Fishman
Chief Executive Officer
Corey Fishman has served as Chief Executive Officer since late 2015 when the company was formed. From 2010 to 2015, Mr. Fishman served as Chief Financial and Chief Operating Officer of Durata Therapeutics, Inc. overseeing all aspects of finance and administration, manufacturing, business development, strategy, international operations and portfolio optimization. While at Durata, he raised substantial capital, including a successful IPO and secondary public offering. Mr. Fishman also led the negotiation and sale of the company to Actavis plc.
Prior to Durata, Mr. Fishman served as Chief Financial Officer of Ganic Pharmaceuticals, Inc., a Warburg Pincus company from 2008 to 2010. From 2002 to 2008, Mr. Fishman served in a leadership role at MedPointe Healthcare, Inc., a private equity backed specialty pharmaceutical company and became the Chief Financial Officer in 2006. Mr. Fishman had responsibility for finance and administration, portfolio optimization, manufacturing, strategy and business development. He led the development and implementation of a new strategic plan, which involved raising capital, restructuring debt, accelerating the growth of existing commercial assets and developing multiple line extensions to enhance future value, culminating in the successful sale of the company to Meda AB. From 1994 to 2002, Mr. Fishman held roles of increasing responsibility in both mid-size and large pharma.
Mr. Fishman serves on the board of BioSpecifics Technology Corporation (Nasdaq: BSTC), a biopharmaceutical company that is building an enterprise on the foundation of its collagenase-based therapies.
Mr. Fishman holds a BA in Economics from the University of Illinois at Urbana-Champaign and an MSM in Finance from the Krannert School of Management at Purdue University.
Judith M. Matthews
Chief Financial Officer
Judy Matthews has served as Chief Financial Officer since late 2015 when the company was formed. From 2012 to 2015, Ms. Matthews served as VP of Finance at Durata Therapeutics, Inc. until its acquisition by Actavis plc. From 2009 to 2012, Ms. Matthews was Head of Financial Planning & Analysis at Bally Total Fitness. From 2004 to 2008, Ms. Matthews served as VP of Finance for the Sterno Group, a subsidiary of Blyth, Inc. Ms. Matthews holds a BA in Accounting from the University of Illinois at Urbana-Champaign and a Master of Management in Finance and Marketing from the Kellogg School of Management at Northwestern University.
Tom Loughman, PhD
Vice President and CMC Head
Tom Loughman, Ph.D. joined Iterum Therapeutics in late 2016 as VP, CMC and Manufacturing. Prior to joining Iterum, Tom served as Director of API Development at Ipsen from 2004 and was a member of their CMC and Dublin manufacturing site leadership teams. With over 20 years experience in the CMC field, Tom also held production management and product development leadership roles across Ipsen’s Technical Operations and R & D functions. He holds a Ph.D. in Pharmaceutics from Trinity College, Dublin and also holds a B.Sc. in Biotechnology from Dublin City University.
Senior Vice President, Legal Affairs
Louise Barrett joined Iterum Therapeutics as Legal Counsel in 2017 having previously served as Associate Counsel with Western Union from 2015 – 2017 and as a member of their Dublin site leadership team. From 2004 – 2015, Ms. Barrett worked as a corporate lawyer with a leading Irish law firm, Mason Hayes & Curran, advising clients in the pharmaceutical, healthcare, technology and venture capital industries.
Ms. Barrett holds a Bachelor of Business and Legal Studies from University College Dublin, Ireland and a Masters in European Law from University College Dublin, Ireland. Ms. Barrett is an Irish practicing solicitor and a member of the Law Society of Ireland and the Law Society of England and Wales.
Steven I. Aronin, MD
Senior Vice President and Head of Clinical Development
Dr. Aronin joined Iterum Therapeutics in 2017. As Senior Director of Clinical Development, Dr. Aronin served in various levels of increasing responsibility from 2017-2020. Most notably, he oversaw the Phase III programs for sulopenem.
Dr. Aronin earned his undergraduate degree from UCLA and his medical degree from Ross University School of Medicine. He completed his training in Primary Care/Internal Medicine as well as his fellowship in Infectious Disease at Yale University School of Medicine. He worked as an Infectious Disease clinician from 1997-2017 at Waterbury Hospital in Waterbury, CT where he was Section Chief, Hospital Epidemiologist, and Scientific Director for the Yale-Waterbury Internal Medicine Residency Program. Dr. Aronin is Associate Clinical Professor of Medicine at Yale University Schools of Medicine, a fellow of the American College of Physicians, a fellow of the Infectious Disease Society of America, and past president of the CT Infectious Disease Society.